J Emerg Med:阿片类药物处方指南是否可减少阿片类药物的滥用?

2016-01-02 MedSci MedSci原创

阿片类药物滥用所致的死亡事件是一个重大的公共卫生问题。与阿片类药物过量使用相关的死亡率从1999年到2008年几乎翻了两番。急性护理设置是阿片类药物处方的主要来源,通常是由于较轻的疾病和慢性非癌性疼痛。

阿片类药物滥用所致的死亡事件是一个重大的公共卫生问题。与阿片类药物过量使用相关的死亡率从1999年到2008年几乎翻了两番。急性护理设置是阿片类药物处方的主要来源,通常是由于较轻的疾病和慢性非癌性疼痛。

本研究旨在确定阿片类药物处方指南是否可降低因轻微和慢性疾病而服用处方阿片类药物的患者比例。

研究人员回顾分析了2012年1月至2014年7月因牙齿、颈部、背部或不确定部位的慢性疼痛而就诊于急诊科的病例记录,并对比指南出现前后患者出院前接受阿片类药物处方的比例。同时调查了参加急救的医生,调查他们关于指南对处方模式,患者的满意度以及医患关系的影响的看法。

研究共纳入了13187名患者,因牙齿、颈部、背部或不确定部位的慢性疼痛而就诊于急诊科后阿片类药物的使用率明显且稳定下降。指南出现之前阿片类药物的处方率为52.7%,而指南出现后阿片类药物的处方率为立即变为29.8%,在其推出后的12-18个月之间为33.8%。因以上疾病就诊的患者其阿片类药物的使用率均有所下降。31个符合条件的医生均完成了调查。所有的调查对象都支持阿片类药物的处方指南。

总而言之,阿片类药物处方指南可显著降低急性护理设置中阿片类药物用于轻微和慢性疼痛的使用率。

原始出处:

Daniel A. del Portal, Megan E. Healy et al.. Impact of an Opioid Prescribing Guideline in the Acute Care Setting. J Emerg Med. doi:10.1016/j.jemermed.2015.06.014.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701516, encodeId=5ec51e0151603, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Nov 14 09:59:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252997, encodeId=743e125299e94, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309009, encodeId=b9cb13090090b, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606794, encodeId=e3ce1606e9485, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-11-14 zchen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701516, encodeId=5ec51e0151603, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Nov 14 09:59:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252997, encodeId=743e125299e94, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309009, encodeId=b9cb13090090b, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606794, encodeId=e3ce1606e9485, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1701516, encodeId=5ec51e0151603, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Nov 14 09:59:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252997, encodeId=743e125299e94, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309009, encodeId=b9cb13090090b, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606794, encodeId=e3ce1606e9485, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-01-04 lhlxtx
  4. [GetPortalCommentsPageByObjectIdResponse(id=1701516, encodeId=5ec51e0151603, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Nov 14 09:59:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252997, encodeId=743e125299e94, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309009, encodeId=b9cb13090090b, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606794, encodeId=e3ce1606e9485, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 04 09:59:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]

相关资讯

JAMA:美国近十年阿片类药物使用情况分析——借鉴意义重大

自从1999年以来,由于处方类阿片镇痛药的非医疗用途的使用导致的死亡率和发病率在美国呈现逐年上升的趋势。在这段时间内,由于这些镇痛药的不当使用导致的急诊室人数上升和药物过量使用导致的死亡不断的上升。 据估计,由于阿片类镇痛药的使用导致的急诊就诊人数从2004年的每十万人中有82.5上升至每十万人中有184.1人。由此可见,处方阿片类镇痛药的滥用已经成为美国医疗卫生的一大问题。 

Lancet Psychiatry:阿片类药物替代疗法(美沙酮vs丁丙诺啡)的死亡风险比较

阿片类药物依赖性增加了过早死亡的风险。使用美沙酮或丁丙诺啡替代阿片类药物治疗可降低死亡风险,尤其是对与药物过量有关的死亡。临床指南推荐美沙酮作为阿片类药物替代治疗的一线药物。该研究的目的是测试丁丙诺啡治疗是否比美沙酮治疗具有较低的死亡风险,通过比较在治疗诱导时,治疗过程药物的转换和治疗后停止用药的全因死亡率进行分析。研究人员在澳大利亚新南威尔士州做了一项所有具有阿片类药物依赖性患者的回顾性队列研究

一周研究进展荟萃:让你知识满满!

通宵工作 癌细胞 β受体阻滞剂 睡眠 阿片类药物 心衰 动脉硬化

JCO:癌症中度疼痛使用低剂量吗啡镇痛,效果显著!

 WHO针对癌症疼痛治疗是基于一种三步、镇痛梯度。第一步是使用非阿片类镇痛药来治疗轻微的疼痛,比如扑热息痛或者非甾体类抗炎药物;第二步是使用弱的阿片类药物,如:可待因或者曲马朵来治疗轻微至中度的疼痛;第三步是使用强效阿片类药物来治疗中度疼痛。尽管这种梯度已经被广泛用于临床治疗癌症引发的疼痛,但是没有被缓解的疼痛仍然对实体瘤或者血液恶性肿瘤患者造成巨大的影响。一个常见的原因就是镇痛治疗不足